Valo Health, Khosla Ventures Acquisition to merge

By The Science Advisory Board staff writers

June 11, 2021 -- Valo Health and Khosla Ventures Acquisition (KVAC) plan to merge to form a publicly traded company with an estimated pro forma market value of approximately $2.8 billion.

Valo is building a fully integrated, end-to-end, artificial intelligence-driven drug discovery platform that aims to improve the success rates for the discovery, development, and approval of new drugs, the companies stated. The Opal Computational Platform, based on longitudinal and omics data, allows information to be shared in parallel at every stage of the drug discovery and development process. Valo's pipeline includes two clinical stage assets and 15 prioritized preclinical assets across cardiovascular, metabolic, and renal; neurodegeneration; and oncology fields.

KVAC is a special purpose acquisition company founded by affiliates of Khosla Ventures. The transaction is anticipated to close in the third quarter of 2021 and is subject to the approval of KVAC's stockholders and the satisfaction or waiver of other customary closing conditions, according to the companies.

Relay Therapeutics acquires ZebiAI for $85M
Relay Therapeutics has acquired ZebiAI, a developer of experimental DNA-encoded library datasets using machine learning for drug discovery. Relay hopes...
Brooklyn ImmunoTherapeutics, NTN complete reverse merger
Brooklyn ImmunoTherapeutics has completed its reverse merger with NTN Buzztime and will trade under the new ticker "BTX." The company will focus on advancement...
Axol Bioscience to merge with Censo Biotechnologies
Provider of induced pluripotent stem cell-derived cells, media, and characterization services Axol Bioscience and contract research organization Censo...
Nautilus Biotechnology to merge with SPAC
Nautilus Biotechnology, a next-generation proteomics company, has entered into a definitive merger agreement with Arya Sciences Acquisition, a special...
Are biotech companies really high-risk investments?
Despite the public perception of the biotech industry as a high-risk investment, a new analysis published in PLOS One on January 6 found that...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter